Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lizhong Xiaopi Granules is a Traditional Chinese Medicine (TCM) compound preparation developed by Yingkerui (Tianjin) Innovative Pharmaceutical Research Co., Ltd. It is currently being investigated in Phase II clinical trials for the treatment of diabetic gastroparesis, specifically targeting the 'Stomach Disharmony and Descent Failure' syndrome (胃失和降证). The formulation is designed to regulate the middle burner and restore the physiological descent of stomach qi, thereby alleviating common gastroparesis symptoms such as abdominal distension, early satiety, and nausea. As a TCM compound, it likely exerts its therapeutic effects through multiple botanical active ingredients that modulate gastric motility and gastrointestinal hormone levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lizhong Xiaopi Granules.